Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mainz Biomed N.V. - Ordinary Shares (NQ: MYNZ )

0.2271 -0.0179 (-7.31%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mainz Biomed N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
2 Million Cancer Diagnoses And 600,000 Cancer Deaths Expected In 2024 – Prevention Is Key To Treatment, And Mainz Biomed Is Leading The Charge
The global population is experiencing a scary increase in colorectal cancer, especially among young people. Colorectal cancer (CRC) diagnoses have been steadily rising since the 1990s; in 1995 the... 
Via Benzinga
Topics Death
Exposures Death
Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium
From Mainz BioMed NV
Via GlobeNewswire
2024 Marks a New Era Of Pharmaceutical Innovation
With Covid-19 finally fading into history, the Covid-19 heroes, namely Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) were forced to redefine their business focus last year, and so, they turned... 
Via Benzinga
Exposures COVID-19
Mainz Biomed Provides Year-End Corporate Review 2023
From Mainz BioMed NV
Via GlobeNewswire
The Latest Analyst Ratings for Mainz Biomed
Via Benzinga
2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer
During the last week of 2023, AstraZeneca PLC (NASDAQ: AZN) agreed to acquire Chinese cancer therapy developer Gracell Biotechnologies Inc. 
Via Benzinga
Is This BioTech Play Severely Undervalued? BioTech Shares Promising Results From Colorectal Study
Via Benzinga
Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees
Hermann Bantleon GmbH (“Bantleon), Shareholder of German AVIA, will Offer the ColoAlert® At-Home Screening Test to Employees Across All Three of Their German Locations, Namely Ulm, Ulm-Nord, and... 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland
From Mainz BioMed NV
Via GlobeNewswire
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
While Pfizer Faced A Setback, Altimmune, Roche And Mainz Biomed Advanced in The Battle Against Obesity And Colorectal Cancer
Obesity has been linked to development of a range of diseases and unfortunately, cancer. More specifically, the National Cancer Institute estimated that colorectal cancer is 1.3 times more likely in... 
Via Benzinga
Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference
From Mainz BioMed NV
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering
From Mainz BioMed NV
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Crude Oil Gains Over 1%; US Budget Deficit Narrows For October
U.S. stocks traded mixed toward the end of trading, with the Dow Jones gaining around 50 points on Monday. The Dow traded up 0.16% to 34,337.33 while the NASDAQ fell 0.11% to 13,783.41. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Edible Garden Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Edible Garden AG Incorporated (NASDAQ: EDBL) shares fell on Monday following third-quarter results. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Mainz Biomed (MYNZ) Stock Is Getting Hammered
Mainz Biomed NV (NASDAQ: MYNZ) shares are trading lower by 46% to $1.21 during Monday's session has entered a securities purchase agreement with institutional investors to raise $5 million through a 
Via Benzinga
Dow Surges 100 Points; Tenax Therapeutics Shares Spike Higher
U.S. stocks traded mostly higher midway through trading, with the Dow Jones gaining around 100 points on Monday. The Dow traded up 0.33% to 34,397 while the NASDAQ fell 0.06% to 13,790. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures US Equities
US Stocks Fall; Tyson Foods Posts Upbeat Earnings
U.S. stocks traded lower this morning, with the Nasdaq Composite falling around 100 points on Monday. Following the market opening Monday, the Dow traded down 0.08% to 34,254.53 while the NASDAQ fell... 
Via Benzinga
Topics Stocks
Exposures US Equities
Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed Partners With Liquid Biosciences In Exclusive Relationship To Harness The Power Of Artificial Intelligence (AI) To Develop Next-Generation Colorectal Screening Test
The integration of Artificial Intelligence (AI) in biotechnology is rapidly gaining momentum, revolutionizing the field of life sciences. AI technologies, such as machine learning and deep learning... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test
Collaboration to utilize cutting-edge AI analysis platform for clinical trials and cancer screening test processing 
From Mainz BioMed NV
Via GlobeNewswire
Mainz Biomed’s (NASDAQ: MYNZ) ColoFuture Study Reveals “Groundbreaking Results”: ColoAlert® Raises The Bar For Colorectal Cancer Detection
--News Direct-- 
Via News Direct
Topics Death
Exposures Death
AI Meets Oncology! Mainz Biomed Inks Pact With Liquid Biosciences To Develop Next-Gen Colorectal Cancer Screening Test
Mainz Biomed N.V. (NASDAQ: MYNZ) inked a pact with Liquid Biosciences, a bio-analytics company leveraging its proprietary AI analysis technology platform (EMERGE), to enhance the  
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.